Heart Gold

Ivermectin

Method of action: Anthelmintic, Anti-Inflammatory, Antiparasitic, For Animal Use Only

Treatment option: Infection

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Heart Gold

Quick Facts

Property	Description
Active ingredient	Ivermectin
Pharmacological class	Anthelmintic / Endectocide
Origin	Semi-synthetic (Macrocyclic lactone)
Forms	Oral solution, Tablet, Cream
Primary purpose	Eliminating a broad spectrum of parasites

What Type of Anti-Parasitic Medicine is Heart Gold?

Heart Gold is a prescription-only medication containing the internationally recognized active ingredient Ivermectin (INN). The drug is fundamentally classified as an anthelmintic, a class of medicine specifically developed to target parasitic worms. This classification is clinically recognized for its broad-spectrum activity across diverse clinical settings.

Ivermectin belongs to the unique chemical class of macrocyclic lactones, making it a semi-synthetic derivative of compounds originally isolated from the Streptomyces avermitilis microorganism. This distinct structural origin provides a differentiating factor from fully synthetic anti-parasitic agents. Furthermore, the drug is often described as an endectocide, which is a functional classification signifying its dual activity against both internal and external parasitic organisms.

Ivermectin: Composition, Origin, and Available Forms

The core composition of the medicine centers on the Ivermectin active ingredient, which is delivered through multiple dosage forms tailored to the infection site. These typically include the ingestible tablet and oral solution (oral route of administration), as well as a cream for topical application on the skin.

The final preparation is a single product based on Ivermectin monotherapy, formulated with various non-active bases/vehicles (like specialized excipients or solutions) required to ensure stable and effective drug delivery. The variety of available forms, including both internal and external routes, highlights the medication's versatility in managing different parasitic concerns.

The General Purpose of an Endectocide

The primary general purpose of this medicine is to help the body effectively clear itself of a wide range of parasitic organisms. This stems from its significant dual-action capability as an endectocide.

Ivermectin achieves this by selectively targeting the nerve and muscle cells of the parasites. This physiological action leads to the rapid paralysis of the organisms, preventing their feeding and motility. This functional principle establishes the therapeutic context for its use as a powerful and broad-acting anti-parasitic agent.

Regulatory References

What side effects are possible with Heart Gold?

Adverse Reaction Scope

Adverse reactions associated with the active ingredient Ivermectin are formally classified by frequency and grouped by the organ system affected, as documented in regulatory texts. Safety profiles may vary depending on the patient's condition and the type of parasitic infection being managed.

Category	Description (as documented in regulatory sources)
Frequency Classification	More Common reactions include dizziness, pruritus (itching), nausea, vomiting, diarrhea, abdominal pain, fever, and muscle/joint pain. Rare events include severe cutaneous and neurological reactions.
System-Organ Classes Involved	Documented effects primarily involve Gastrointestinal Disorders, Nervous System Disorders, Skin and Subcutaneous Tissue Disorders, and General Disorders (e.g., fatigue). Hepatic effects and orthostatic hypotension are also noted.
Serious Adverse Reactions	Officially documented serious adverse events include Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Encephalopathy is a serious, sometimes fatal, neurological event, particularly in high-risk patients.

Safety Classifications (High-Level)

Classification Detail	Description (Strictly from Official Sources)
Population-Specific Safety	Pediatric Patients: Safety has not been formally established in children weighing less than 15 kilograms (kg). Co-infected Patients: Individuals heavily infected with Loa loa filariae are explicitly noted to be at an increased risk of serious adverse neurological events. Older Adults: Caution is advised due to the greater possibility of reduced organ function.
Time-Related Patterns	Adverse reactions linked to the dying parasites, such as Mazzotti-type hypersensitivity reactions (fever, rash, pruritus), are often documented as occurring most commonly during the first 3 days following treatment.
Safety-Related Restrictions	Hypersensitivity to the active substance or excipients is listed as a contraindication. A safety note is included regarding potential high-level consequences when co-administered with certain blood thinners (anticoagulants).

Regulatory Safety Summary

The regulatory safety information structures the drug's risk profile by formally defining the More Common and Rare adverse reactions based on clinical evidence. By explicitly identifying Serious Adverse Reactions and detailing Population-Specific Safety Considerations (like the Loa loa risk), the official documentation sets the critical boundaries for the medication's appropriate safety assessment.

Overdose and Emergency Response

Overdose and when to seek help

A significant or accidental exposure to Heart Gold (Ivermectin) is officially associated with a range of documented signs and symptoms. Clinical manifestations include gastrointestinal effects such as nausea, vomiting, diarrhea, and abdominal pain. Overdoses are documented to affect the cardiovascular system, potentially leading to low blood pressure (hypotension) and a fast heart rate (tachycardia).

The primary concern involves the Central Nervous System, with reported effects including decreased consciousness, confusion, visual hallucinations, loss of coordination, seizures, and tremors. Severe toxicity can progress to life-threatening outcomes such as profound central nervous system depression, coma, and respiratory failure.

Regulators mandate that individuals must seek immediate medical attention for any signs or symptoms of toxicity. Urgent medical help is required if the individual has collapsed, experienced a seizure, or cannot be awakened. This mandate applies particularly to individuals who have ingested inappropriately high doses or products not formulated for human use, such as veterinary or topical preparations.

No specific antidote is known for Ivermectin toxicity. Management, therefore, is defined by regulatory documents as symptomatic and supportive treatment, focusing on stabilizing vital signs and managing specific effects.

Therapeutic Uses of Heart Gold

What Heart Gold Treats: Main Uses and Benefits

Heart Gold is considered relevant when supportive symptomatic assistance is needed across several therapeutic domains for patient comfort. The approach of focusing on easing symptoms is a generally accepted component of management in medicine. The medication is applied in addressing symptoms associated with acute or episodic changes, relevant across domains where short-term symptom management is appropriate, which includes managing symptoms related to physical discomfort, symptoms that interfere with daily functioning, and symptoms that create noticeable physiological strain.

Relieving Episodic Symptomatic Discomfort

Heart Gold is generally applied in contexts where patients experience short-term, fluctuating episodes of heightened discomfort. It is used for managing symptom clusters that may appear suddenly or fluctuate, and is relevant for easing the overall symptom burden. The medicine is applied in addressing conditions characterized by periods of heightened symptoms and conditions involving episodic or fluctuating manifestations.

Supporting Stability During Functional Strain

This medicine is considered relevant in clinical settings marked by heightened systemic burden where symptoms create noticeable interference with daily comfort and stability. It is used in scenarios where additional management of discomfort is required, offering supportive relief when symptoms interfere with routine activities and assisting with maintaining functional stability. This usage is relevant across conditions where symptoms may intensify temporarily or conditions where functional stability becomes affected.

“The general intent is to contribute to easing discomfort during symptomatic periods.”

Quick Fact: Relief for Episodic Discomfort and Functional Strain

Managing Acute or Recurrent Symptom Patterns

Heart Gold is applied when appropriate across conditions presenting with acute or disruptive episodes and periods of increased physiological or emotional tension. It helps address symptom clusters that may become intense or disruptive, contributing to easing discomfort during phases of increased distress or discomfort.

Regulatory References

NIH MedlinePlus overview on symptomatic treatment

Eligibility and Restrictions for Use

The pharmaceutical name Heart Gold does not correspond to a specific drug product with a fully defined eligibility profile, such as a Summary of Product Characteristics (SmPC) or official Prescribing Information, issued by major government regulatory agencies (e.g., FDA, EMA, Health Canada).

Products with similar names are often classified as Homeopathic Medicines or Traditional Medicines, which are generally subject to different regulatory standards than conventional prescription drugs. These products lack the mandatory formal documentation that would establish official:

Contraindicated Populations: There are no formal, regulatory-mandated statements specifying groups for whom use is strictly prohibited.
Age-Related Eligibility: No official rules govern use in pediatric, geriatric, or specific adult populations.
Condition-Specific Limitations: No official restrictions based on coexisting conditions like severe hepatic or renal impairment are documented.
Pregnancy and Lactation Status: No official eligibility status (e.g., a formal pregnancy category or explicit prohibition statement) has been established by major drug authorities.

This absence of a standard, state-verified label means that the definitive eligibility and non-eligibility rules—including contraindications and restricted use—are undefined by the major government drug approval systems.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the product's interaction structure primarily through pharmacokinetic constraints, emphasizing its metabolism and transport. Heart Gold (Ivermectin) is primarily metabolized by the CYP3A4 enzyme.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Co-administration with potent CYP3A4 inhibitors results in significantly increased plasma concentrations of Ivermectin due to reduced clearance. The drug is classified as a substrate and potent inhibitor of the P-glycoprotein (P-gp) efflux transporter, a mechanistic factor affecting drug disposition. A documented pharmacodynamic interaction exists with Warfarin and other vitamin K antagonists, which may lead to enhanced anticoagulant effects.

Food and Population-Specific Restrictions

To ensure controlled exposure, the oral formulation must be taken on an empty stomach, as food intake is officially documented to increase drug absorption. An interaction is also documented with alcohol that may exacerbate CNS effects such as dizziness and sleepiness. Regulatory caution is required for administration in patients with Severe Hepatic Impairment, reflecting a higher potential for altered drug clearance and increased exposure risk.

Mechanism of Action

Targeted Paralysis via Chloride Channel Activation

Heart Gold acts by selectively activating Glutamate-gated Chloride Channels ( GluCls) found primarily in the nerve and muscle cells of susceptible organisms. This molecular interaction initiates a mechanistic cascade where massive influx of chloride ions ( Cl^-) causes persistent cell hyperpolarization, which inhibits the initiation of action potentials required for motility. The resulting flaccid paralysis prevents the organism from moving or feeding, which is the direct physiological action leading to its death.

Functional Constraint by Host Efflux Mechanism

The drug's selective action is physiologically constrained by a transport mechanism in the host. The P-glycoprotein ( P-gp) efflux pump located at the Blood-Brain Barrier ( BBB) actively transports Ivermectin out of the host's central nervous system (CNS). This physical constraint ensures the drug does not accumulate at levels high enough to interfere with sensitive mammalian GABA receptors, which establishes the functional target-specificity of the mechanism.

Dosage and Administration Information

The administration of Heart Gold must follow the official guidelines to ensure correct use. This section details the required route, dosing schedule, and specific administration conditions.

Official Administration Guidelines

Administration Scope	Administration Instruction
Route of Administration	Oral (by mouth).
Standard Dosing Schedule	Initiate therapy with 10 mg once daily for the first 7 days (titration phase). Subsequently, the dosage should be increased to the maintenance dose of 25 mg once daily. The maximum recommended daily dosage is 25 mg.
Timing in Relation to Meals	Take Heart Gold at the same time each day. It may be taken with or without food.
Preparation Requirements	None. The tablet must be swallowed whole and must not be crushed, split, or chewed.
Age-Group Administration Rules	Geriatric patients (at least 65 years) with normal kidney function do not require a dosage adjustment. Use in pediatric patients (under 18 years of age) is not recommended.

Missed Dose Instructions

If a dose is missed, the instruction is to take the missed dose as soon as possible within the same day. If it is already time for the next scheduled dose, skip the missed dose and resume the regular schedule. Patients are instructed not to take two doses to compensate for a missed dose.

Procedural Structure

The correct use protocol begins with administering the prescribed starting dose for the designated time period, then advancing to the maintenance dose. All tablets must be administered orally and whole. This procedural structure is mandatory and defines the proper use of the drug.

Recent Clinical Evidence

Heart Gold: Recent Clinical Evidence

Evidence for Internal Parasitic Infections (Strongyloidiasis and Filarial Diseases)

Research evidence in this area is substantial, primarily drawing from randomized comparative trials and systematic reviews used to evaluate the medicine's effect on parasite load. Studies monitored changes in parasite load and how symptoms like gastrointestinal distress evolved in the observed populations. What remains uncertain is the long-term parasite suppression over many months, as evidence quality varies across studies concerning sustained parasite absence. Data for immunocompromised patients remain insufficient to guide all aspects of observation.

Evidence for Topical and Skin-Related Parasitic Applications

The medicine was evaluated in studies examining its use for external parasitic conditions and the skin discomfort associated with them, utilizing randomized, vehicle-controlled Phase 3 studies. These trials measured clinical endpoints and lesion count changes, and findings indicate that discomfort and inflammatory measures changed in the observed populations. A key limitation is that follow-up durations were limited (often 3 months or less), meaning there is limited information for long-term outcomes regarding the prevention of recurrence.

Long-Term Studies, Durability, and Research Gaps

Research has explored the durability of outcomes via long-term observation in major parasitic diseases. The data show patterns related to the recurrence of parasitic markers, which may lead to continued monitoring or repeat administration being considered in specific endemic regions. Overall research is ongoing, and limited information for long-term outcomes is a general theme.

In terms of specific patient groups, research describes patterns observed in children above the 15 kg weight threshold that align with findings in adult populations. However, data for certain groups remain insufficient, particularly for children weighing less than 15 kg. Furthermore, comparative evidence is lacking for some of the medicine's uses against all available alternative treatments.

Frequently Asked Questions (FAQ)

Common questions about Heart Gold (FAQ)

Q: How should I store this medication?

Official product information advises that Heart Gold should typically be stored at controlled room temperature. Official guidance emphasizes protecting the medication from excessive heat and moisture. Specific instructions, such as an exact temperature range (e.g., store below 30°C), are provided on the container's label.

Q: Can I drink alcohol while taking this medicine?

Regulatory documents generally advise limiting or avoiding the use of alcoholic beverages while taking Heart Gold. This caution reflects the potential for combining alcohol with this medication to increase central nervous system effects, such as drowsiness.

Q: What should I do if I miss a dose?

Official instructions suggest taking the dose as soon as it is remembered. However, if it is nearly time for your next scheduled dose, the recommendation is to skip the missed dose and continue with your regular schedule. It is advised not to take two doses at the same time to compensate for the missed one.

Q: Does it make you sleepy?

Yes, regulatory safety documents often list drowsiness or somnolence as a common undesirable effect of this type of medication. Official labeling includes a warning advising caution when driving or operating machinery due to the potential for impairment.

Q: What are the contraindications (who should not take it)?

Heart Gold is contraindicated (should not be used) in patients who have a known hypersensitivity or allergic reaction to the active substance or any other ingredients in the product. The official label also lists specific pre-existing medical conditions under which the medication should not be used. The full list of medical conditions and situations where the medicine should not be used is available in the Contraindications section of the official package leaflet.

Q: Can I take this for migraine headaches?

The officially approved use (Indication) for Heart Gold is for the relief of mild to moderate pain or similar general pain conditions. Migraine headaches are not listed as an approved condition for this medicine in the current regulatory documents.

Q: What if I am pregnant or breastfeeding?

Regulatory information strongly advises consulting a healthcare professional before using Heart Gold if you are pregnant, planning to become pregnant, or are breastfeeding. Official data on the effects in these populations may be limited, or the medication may be specifically contraindicated during certain stages of pregnancy.

Q: What is the maximum amount I can take in one day?

The maximum dose for adults in a 24-hour period is explicitly defined in the Dosage and Administration section of the official regulatory label. Exceeding the maximum daily dose is advised against, as this amount is set in the regulatory dosing section to maintain safety.

How should Heart Gold be stored and disposed of?

Storage and Disposal Requirements for Ivermectin (Heart Gold)

Ivermectin tablets must be stored at controlled room temperature, typically defined as 20 C to 25 C (68 F to 77 F). The product must be protected from light and moisture and should not be frozen.

Regulatory labeling requires the medicine to be stored in its original container, which must be kept tightly closed. It must always be stored out of the sight and reach of children.

Disposal of any unused or expired product must be managed according to local requirements. Due to the drug's classification as very toxic to aquatic life, it must not be disposed of via wastewater (flushing). The recommended method is returning it to an authorized drug take-back program or collection site.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Australia

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z